5-Fluorouracil can cross brain-blood barrier and cause encephalopathy: should we expect the same from capecitabine? A case report on capecitabine-induced central neurotoxicity progressing to coma

被引：43

作者：

Formica, V ^{[1
]}

Leary, A ^{[1
]}

Cunningham, D ^{[1
]}

Chua, YJ ^{[1
]}

机构：

[1] Royal Marsden Hosp, Dept Med, Sutton SM2 5PT, Surrey, England

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2006年 / 58卷 / 02期

关键词：

5-fluorouracil; encephalopathy; capecitabine;

D O I：

10.1007/s00280-005-0159-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Purpose: Capecitabine is a relatively new oral fluoropyrimidine currently licensed for the treatment of colorectal and breast cancer. Results: It has the advantage of oral administration with good tolerability and comparable activity to intravenous 5-fluorouracil. Central neurotoxicity has been described in 5-fluorouracil-treated patients but there is little data regarding capecitabine. We report here a case of reversible capecitabine-induced encephalopathy progressing to coma. Discussion: Literature on fluoropyrimidine-related neurotoxicity will also be reviewed and possible mechanisms of the drug or its metabolites crossing the blood-brain barrier will be discussed.

引用

页码：276 / 278

页数：3

共 14 条

[1]

Demonstration of the existence of mRNAs encoding N1/cif and N2/cit sodium/nucleoside cotransporters in rat brain [J].

Anderson, CM ;

Xiong, W ;

Young, JD ;

Cass, CE ;

Parkinson, FE .

MOLECULAR BRAIN RESEARCH, 1996, 42 (02) :358-361

[2]

BOURKE RS, 1973, CANCER RES, V33, P1735

[3]

First-line oral capecitabine therapy in metastatic colorectal cancer:: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin [J].

Cassidy, J ;

Twelves, C ;

Van Cutsem, E ;

Hoff, P ;

Bajetta, E ;

Boyer, M ;

Bugat, R ;

Burger, U ;

Garin, A ;

Graeven, U ;

McKendrick, J ;

Maroun, J ;

Marshall, J ;

Osterwalder, B ;

Pérez-Manga, G ;

Rosso, R ;

Rougier, P ;

Schilsky, RL .

ANNALS OF ONCOLOGY, 2002, 13 (04) :566-575

[4]

Couch Linda S B, 2003, Clin Colorectal Cancer, V3, P121, DOI 10.3816/CCC.2003.n.019

[5]

PLATELET-DERIVED ENDOTHELIAL-CELL GROWTH-FACTOR THYMIDINE PHOSPHORYLASE EXPRESSION IN NORMAL-TISSUES - AN IMMUNOHISTOCHEMICAL STUDY [J].

FOX, SB ;

MOGHADDAM, A ;

WESTWOOD, M ;

TURLEY, H ;

BICKNELL, R ;

GATTER, KC ;

HARRIS, AL .

JOURNAL OF PATHOLOGY, 1995, 176 (02) :183-190

[6]

Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug [J].

Mata, JF ;

García-Manteiga, JM ;

Lostao, MP ;

Fernández-Veledo, S ;

Guillén-Gómez, E ;

Larrayoz, IM ;

Lloberas, J ;

Casado, FJ ;

Pastor-Anglada, M .

MOLECULAR PHARMACOLOGY, 2001, 59 (06) :1542-1548

[7]

Toxic encephalopathy induced by capecitabine [J].

Niemann, B ;

Rochlitz, C ;

Herrmann, R ;

Pless, M .

ONCOLOGY, 2004, 66 (04) :331-335

[8]

Phuphanich S, 1994, J Neuroimaging, V4, P114

[9]

Neurologic disorder in a 65-year-old man after treatment of colon cancer - Multifocal inflammatory leukoencephalopathy related to combination chemotherapy with fluorouracil and levamisole [J].

Recht, LD ;

Primavera, JM ;

Buchbinder, BR ;

Avgeropoulos, N ;

Hedley-Whyte, ET ;

Colvin, RB .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (07) :512-519

[10]

Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency [J].

Shehata, N ;

Pater, A ;

Tang, SC .

CANCER INVESTIGATION, 1999, 17 (03) :201-205

← 1 2 →